SOLUTIONS

SOLUTIONS

Eurofins Discovery built its industry-leading reputation on successfully delivering best-in-class drug discovery services to any organization, large or small. No matter where you are in the preclinical process—or if you need full end-to-end solutions—our experts support you every step of the way with purpose, precision, and innovation.
 
As a global leader in drug discovery for over 40 years, we have strategically amassed a deep and broad range of over +10,000 assays for every type of research, as well as a full team of industry experts across disciplines to collaborate with you. Delve into all the ways we can work together by choosing the best path forward for you from our comprehensive services.

Small Molecules
Biotherapeutics
Integrated Drug Discovery
Therapeutic Areas
Research Phase
Custom Solutions

Biotherapeutics

Since the approval of human insulin and the first monoclonal antibody (mAb), there has been a surge in the discovery and development of biologics, leading to the approval of hundreds of large molecules spanning diverse therapeutic areas. They have accounted for approximately one-third of the FDA-approved drugs over the past decade with no end in sight. As a result, the biologics market is expected to reach over $800 billion by 2033.
New treatment modalities – mRNA vaccines, multi-specific antibodies, ADCs, gene therapies and CAR-T cells, and others – are positively transforming the treatment landscape for cancer, rare diseases, and emerging pathogens through novel MOAs.
 
Despite the thousands of biologics undergoing preclinical and clinical investigation globally, the track from discovery to market approval is expensive and risky, made even more uncertain by the historically high rate of translational failure. Each type of biologic has unique challenges. Their biological complexity introduces many difficulties with characterization and analytical assessment, consistent manufacturing and scale-up, stability, and formulation.
 
Eurofins is your trusted partner for every step in biotherapeutics discovery. Our seasoned experts can help you navigate early target validation and antigen generation through manufacturability assessment, immunogenicity testing, and preclinical development across various treatment modalities, including mAbs, peptides, proteins, viral vectors and more.
 
Read our latest blog.
 
Request a consultation with our biotherapeutics discovery team.

Biotherapeutics image
Key Areas

Learn about our assay development, in vitro pharmacology, and reagent generation and qualification to ensure high-quality reagents and expertise for your preclinical discovery.

Explore our comprehensive antibody discovery services using in vitro and in vivo platforms to generate high-quality therapeutic antibodies.

Uncover high-performing antibody candidates with Eurofins Discovery's comprehensive antibody characterization services to accelerate your therapeutic development.

Enhance the potential of your lead molecule with Eurofins Discovery's in silico optimization and humanization services, improving stability, reducing immunogenicity, and more.

Explore how Eurofins Discovery supports end-to-end ADC programs with expertise in linker-payload design and synthesis, bioconjugation, DAR analysis, and characterization.

Evaluate stability, developability, and biophysical properties to mitigate risks and optimize biotherapeutics lead selection, formulation, and manufacturing.

Discover how our T-cell, cytokine, and flow cytometry assays can help identify and mitigate problematic drug-induced immune responses in biotherapeutics development.

We provide stable cell line generation, optimization and downstream process development, ensuring scalable, high-quality biotherapeutic protein production for preclinical studies.

Explore Eurofins Discovery’s gene and cell therapy workflows to streamline your path from R&D to IND approval.